ORLANDO, Fla., October 22, 2019 — — Immune Therapeutics, Inc. (OTCQB: IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS announced today that Dr. Robert Buckheit, Jr. will join the Scientific Advisory Board (“SAB”) of Immune Therapeutics.
”Immune Therapeutics is fortunate to have an individual as capable as Dr. Buckheit helping guide our development and science,” stated Mike Handley, Chief Executive Officer of Immune. He also stated, “As we move through clinical trials and towards commercialization, we will need to further refine our development and technical strategies, and Dr. Buckheit’s expertise and history of developing drugs is a perfect fit with the needs of Immune.”
Dr. Buckheit is the latest of a string of exceptional and distinguished professionals to join the SAB as Immune Therapeutics continues to restructure and strengthen its base of researchers, physicians, public health officials and business leaders, complementing its endeavors to broaden its efforts in emerging markets.
Dr. Buckheit is the Founder, President and CSO of ImQuest BioSciences and the Co-Founder, Executive Vice President and CSO of ImQuest Life Sciences. He has developed and managed infectious disease, inflammatory disease and cancer research programs for commercial, academic and government clients as Director of Infectious Disease Research at both the Southern Research Institute and at TherImmune Research Corporation/Gene Logic Inc. Dr. Buckheit is a member of the Board of Directors of The Weinberg Center for the Performing Arts in Frederick, Maryland and a member of the Scientific Advisory Board of Oyagen, Inc. He has served as President of the International Society for Antiviral Research and as a member of the Editorial Review Board of the journal, Antiviral Research.
Having worked in the preclinical development of anti-infective agents since 1989, Dr. Buckheit has led the development of dozens of compounds to the IND stage of development, and has authored over 200 peer-reviewed manuscripts throughout his career. Dr. Buckheit received a B.S. in Biology from Lehigh University in 1982, a Ph.D. in Microbiology and Immunology from Duke University in 1986 and completed a postdoctoral fellowship at The University of North Carolina at Chapel Hill in 1989.
“We are excited to welcome Dr. Buckheit to the Immune Therapeutics’ scientific team. He has demonstrated strong leadership and success in the clinical development of numerous small molecules, vaccines, and biologics, has led countless successful collaborations with federal, academic and pharmaceutical entities, and has demonstrated overall superior skill and scientific excellence in the pharmaceutical and biotechnology drug discovery field,” stated Dr. Roscoe M. Moore, Jr., DVM, MPH, Ph.D., DSc, Chair of the Board of Directors of Immune Therapeutics.
“It is an honor to join the SAB of Immune Therapeutics and become a part of an exciting and innovative platform of product development programs focused on critical issues in inflammation, cancer and infectious diseases. I look forward to playing a role in the scientific development of these products and expediting their clinical development and commercialization.”
ABOUT IMMUNE THERAPEUTICS, INC.
Immune Therapeutics Inc. is a late stage clinical stage biopharmaceutical company focused on the development and commercialization of our highly innovative immunotherapies. IMUN is a biotechnology company developing T-cell activation immunotherapies to achieve immunomodulation in patients with autoimmune and inflammatory diseases, cancer and infectious disease.
Forward Looking Statements
Statements contained in this letter that are not statements of historical fact are intended to be and are hereby identified as “forward-looking statements” for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Generally, forward-looking statements include expressed expectations of future events and the assumptions on which the expressed expectations are based, including but not limited to the company’s intended restructuring and move into the pet market. All forward-looking statements are inherently uncertain as they are based on various expectations and assumptions concerning future events and they are subject to numerous known and unknown risks and uncertainties which could cause actual events or results to differ materially from those projected. The Company undertakes no obligation to update or revise this communication to reflect future developments except as otherwise required by the Securities Exchange Act of 1934. This release may contain forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to, the possibility that some or all the matters and transactions considered by the Company may not proceed as contemplated, and by all other matters specified in the Company’s filings with the Securities and Exchange Commission. These statements are made based upon current expectations that are subject to risk and uncertainty. The Company does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company’s filings with the Securities and Exchange Commission (www.sec.gov), including its recent periodic reports.